Details for Patent: 9,248,123

Which drugs does patent 9,248,123 protect, and when does it expire?

Patent 9,248,123 protects CONTRAVE and is included in one NDA.

This patent has twenty-two patent family members in twelve countries.

Summary for Patent: 9,248,123

Title:	Methods of providing weight loss therapy in patients with major depression
Abstract:	Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
Inventor(s):	Dunayevich; Eduardo (San Diego, CA), Tollefson; Gary (Indianapolis, IN)
Assignee:	Orexigen Therapeutics, Inc. (La Jolla, CA)
Application Number:	12/987,909
Patent Claim Types: see list of patent claims	Use; Dosage form; Composition; Formulation;

Drugs Protected by US Patent 9,248,123

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes						USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

International Family Members for US Patent 9,248,123

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011203867
Australia	2016201325
Brazil	112012016783
Canada	2785822
China	102724878